BDSX Share Price | Biodesix, Inc. Stock Analysis & Recommendation

Q: How big is Biodesix, Inc.?

Market Cap: As of Jun 18, Biodesix, Inc. has a market capitalization of 41.70 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Biodesix reported net sales of 74.47 million. During the same period, the company experienced a net profit loss of 40.42 million.Balance Sheet Snapshot: As of Dec 24, the shareholder's funds were recorded at 20.88 million, while total assets amounted to 99.18 million.

Q: What does Biodesix, Inc. do?

Overview:Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:- Most recent Net Sales: 18 Million (Quarterly Results - Mar 2025)- Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025)- Market-cap: USD 41.70 Million (Micro Cap)Key Metrics:- P/E: NA (Loss Making)- Industry P/E: NA- Dividend Yield: 0.00%- Debt Equity: 1.82- Return on Equity: -350.83%- Price to Book: 3.77Contact Details:- Address: 2970 Wilderness Place, Suite 100, BOULDER CO: 80301- Tel: 1 303 4170500- Fax: 1 303 4179700- Website: https://www.biodesix.com/

Q: Should I buy, sell or hold Biodesix, Inc.?

Based on the current situation of Biodesix, Inc., it would be prudent to hold your position rather than buy or sell. The company has shown poor long-term growth, with an operating profit declining at an annual rate of -24.88% over the last five years. Recent results indicate significant challenges, including the lowest operating cash flow at USD -41.97 million and an extremely high debt-equity ratio of 403.09%. Additionally, the company is facing risks with negative EBITDA, and while the stock has generated a return of 0% over the past year, profits have only risen by 15%. However, it's worth noting that institutional investors hold a substantial 46.37% of the stock, suggesting that they may have greater resources to analyze the company's fundamentals.Given these factors, holding may be the best course of action until there are clearer signs of improvement in the company's financial health.

Q: Is Biodesix, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Biodesix, Inc. has changed from sideways to mildly bearish. The current technical stance is bearish, driven by daily moving averages indicating bearish momentum and weekly Bollinger Bands also signaling a bearish trend. While the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall indicators suggest weakness. Additionally, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -78.01% versus the S&P 500's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

22.67 k

Shareholding (Dec 2025)

FII

2.12%

Held by 14 FIIs

DII

91.76%

Held by 6 DIIs

Promoter

0.00%

How big is Biodesix, Inc.?

22-Jun-2025

As of Jun 18, Biodesix, Inc. has a market capitalization of 41.70 million, with net sales of 74.47 million and a net profit loss of 40.42 million over the last four quarters. Shareholder's funds are 20.88 million, and total assets are 99.18 million.

View full answer

What does Biodesix, Inc. do?

22-Jun-2025

Biodesix, Inc. is a U.S. company that develops blood-based diagnostic tests for oncology, classified as a micro-cap with a market cap of $41.70 million. As of March 2025, it reported net sales of $18 million and a net loss of $11 million.

View full answer

Should I buy, sell or hold Biodesix, Inc.?

22-Jun-2025

Who are in the management team of Biodesix, Inc.?

22-Jun-2025

As of March 2022, the management team of Biodesix, Inc. includes Mr. Robert Cawthorn as Chairman of the Board and Mr. David Brunel as Chief Executive Officer and Director.

View full answer

Is Biodesix, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Biodesix, Inc. shows a mildly bearish trend with daily moving averages and Bollinger Bands indicating bearish momentum, despite some mildly bullish MACD signals, and has underperformed the S&P 500 with a year-to-date return of -78.01%.

View full answer

Compare Biodesix, Inc. with Similar Stocks

Nutex Health, Inc.Precipio, Inc.Invitae Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -12.07% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -5.37

Risky -

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 170 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-18.47

Return on Equity

2,267.54%

Price to Book

-98.98

Revenue and Profits:

Net Sales:

29 Million

(Quarterly Results - Dec 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

122.14%

6 Months

80.57%

1 Year

-8.79%

2 Years

-45.11%

3 Years

775.72%

4 Years

-60.34%

5 Years

-95.84%

Biodesix, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

24.50%

EBIT Growth (5y)

-12.07%

EBIT to Interest (avg)

-5.37

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

1.82

Sales to Capital Employed (avg)

1.49

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

40.34%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-98.98

EV to EBIT

-6.25

EV to EBITDA

-7.56

EV to Capital Employed

6.72

EV to Sales

2.52

PEG Ratio

Dividend Yield

ROCE (Latest)

-107.50%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 7 Schemes (6.12%)

Foreign Institutions

Held by 14 Foreign Institutions (2.12%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 32.11% vs 9.00% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 54.02% vs 24.35% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "28.80",
          "val2": "21.80",
          "chgp": "32.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.60",
          "val2": "-5.70",
          "chgp": "89.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.10",
          "val2": "2.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.00",
          "val2": "-8.70",
          "chgp": "54.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-68.40%",
          "val2": "-323.60%",
          "chgp": "25.52%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 24.12% vs 45.21% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 17.72% vs 17.66% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "88.50",
          "val2": "71.30",
          "chgp": "24.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.20",
          "val2": "-28.80",
          "chgp": "22.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.70",
          "val2": "7.10",
          "chgp": "8.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.40",
          "val2": "-1.60",
          "chgp": "75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-35.30",
          "val2": "-42.90",
          "chgp": "17.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-313.70%",
          "val2": "-480.30%",
          "chgp": "16.66%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

28.80

21.80

32.11%

Operating Profit (PBDIT) excl Other Income

-0.60

-5.70

89.47%

Interest

2.10

Exceptional Items

-0.00

Consolidate Net Profit

-4.00

-8.70

54.02%

Operating Profit Margin (Excl OI)

-68.40%

-323.60%

25.52%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 32.11% vs 9.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 54.02% vs 24.35% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

88.50

71.30

24.12%

Operating Profit (PBDIT) excl Other Income

-22.20

-28.80

22.92%

Interest

7.70

7.10

8.45%

Exceptional Items

-0.40

-1.60

75.00%

Consolidate Net Profit

-35.30

-42.90

17.72%

Operating Profit Margin (Excl OI)

-313.70%

-480.30%

16.66%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 24.12% vs 45.21% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 17.72% vs 17.66% in Dec 2024

All Annual Results

Company CV

About Biodesix, Inc.

Biodesix, Inc.

Pharmaceuticals & Biotechnology

Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.

Company Coordinates

Company Details

2970 Wilderness Place, Suite 100 , BOULDER CO : 80301

Tel: 1 303 4170500

https://www.biodesix.com/

Registrar Details